Skip to main content
Clinical Trials/IRCT20221202056684N1
IRCT20221202056684N1
Completed
Phase 3

The effect of ultrasound guided intramuscular injection of botulinum toxin (type A) in the distal of the vastus lateralis muscle on pain relief and performance improvement in patients with patellofemoral pain syndrome: A randomized clinical trial

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Patellofemoral pain syndrome.
Sponsor
Shahid Beheshti University of Medical Sciences
Enrollment
52
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients aged 18 to 45 years
  • Clinical diagnosis of PFP syndrome for more than 3 months
  • Pain rating (out of 10\) 4 or more
  • Failure to respond to treatment despite receiving at least 8 weeks of non\-invasive treatment including exercise therapy, exercise therapy and physical therapy

Exclusion Criteria

  • Presence of knee joint effusion
  • Presence of any evidence in favor of other tibiofemoral pathologies (patellar tendinopathy, presence of evidence of tibiofemoral osteoarthritis or patellofemoral joint space narrowing or arthrosis on radiographs (Kellgren\-Lawrence grade II or higher), meniscal tear, knee instability)
  • Evidence in favor of spinal canal stenosis, lumbar radiculopathy, neuropathy and lower limb neuronal damage
  • Any intra\-articular injection of the knee in the last 6 months (including hyaluronic acid, ozone or steroids)
  • Body mass index \> 35
  • Previous knee surgery
  • Evidence of injury or inflammatory arthritis of the hip joint
  • Allergy to BoNT\-A

Outcomes

Primary Outcomes

Not specified

Similar Trials